Literature DB >> 11672896

Laboratory testing of whole cell pertussis vaccine: a WHO proficiency study using the Kendrick test.

D Xing1, R G Das, T O'Neill, M Corbel, N Dellepiane, J Milstien.   

Abstract

Whole cell pertussis vaccine (WCV), commonly in combination with vaccines for diphtheria and tetanus, has an important role in reducing morbidity and mortality among children in most parts of the world. Testing to assure the efficacy of such vaccines is essential. We have, therefore, carried out, under the Global Training Network (GTN) of the Department of Vaccines and Biologicals at the World Health Organization (WHO), a proficiency study involving 13 laboratories in 12 countries that routinely test WCV. Two vaccine samples were tested in this study and represented samples which were expected clearly either to pass (sample B, a full strength vaccine) or to fail (sample A, 1/8 strength of vaccine B). Data from this study showed good performance by the majority of participants. Most assays were statistically valid and were carried out to the level of precision achieved for these assays in previous studies. This study also indicated that, relative to the assay precision, the in-house reference (IHR) preparations are in general accurately calibrated. Statistically valid assays of the sub-potent vaccine, A, showed it to fail in all except one laboratory. Statistically valid assays of the potent vaccine, B, showed it to pass in all laboratories. Nevertheless, the between laboratory variability of estimates for vaccine B, and for comparisons of the two vaccine samples suggested that there are some differences in results in different laboratories. The introduction of a common working standard may assist in reducing inter-laboratory variation. This study has shown clearly satisfactory performance by most laboratories. However, a serious problem was detected in one laboratory where the sub-potent vaccine A could have been passed and was not distinguished from the eight-fold more potent vaccine B. There were also indications of possible problems in several other laboratories, where IHR preparation may not be accurately calibrated or where vaccine samples A and B may not be completely distinguished. Although this study provides reassurance that most laboratories perform well, it demonstrates the essential role of ongoing proficiency studies in high-lighting problems.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11672896     DOI: 10.1016/s0264-410x(01)00372-3

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Molecular epidemiology of Bordetella pertussis and analysis of vaccine antigen genes from clinical isolates from Shenzhen, China.

Authors:  Shuang Wu; Qinghua Hu; Chao Yang; Haijian Zhou; Hongyu Chen; Yanwei Zhang; Min Jiang; Yuxiang He; Xiaolu Shi
Journal:  Ann Clin Microbiol Antimicrob       Date:  2021-08-18       Impact factor: 3.944

2.  Animal testing for vaccines. Implementing replacement, reduction and refinement: challenges and priorities.

Authors:  Arnoud Akkermans; Jean-Michel Chapsal; Eliana M Coccia; Hilde Depraetere; Jean-François Dierick; Parichat Duangkhae; Sunil Goel; Marlies Halder; Coenraad Hendriksen; Robin Levis; Koraphong Pinyosukhee; Dieter Pullirsch; Gautam Sanyal; Li Shi; Robert Sitrin; Dean Smith; Paul Stickings; Eriko Terao; Sylvie Uhlrich; Laura Viviani; Jim Webster
Journal:  Biologicals       Date:  2020-10-08       Impact factor: 1.856

3.  Characterization of Bordetella pertussis Strains Isolated from India.

Authors:  Shweta Alai; Manish Gautam; Sonali Palkar; Jitendra Oswal; Sunil Gairola; Dhiraj P Dhotre
Journal:  Pathogens       Date:  2022-07-14

4.  Evaluation of the Potency of the Pertussis Vaccine in Experimental Infection Model with Bordetella pertussis: Study of the Case of the Pertussis Vaccine Used in the Expanded Vaccination Program in Algeria.

Authors:  Khedidja Tahar Djebbar; Mounia Allouache; Salim Kezzal; Fouzia Benguerguoura; Chafia TouilBoukoffa; Ines Zidi; Rachida Raache; Hadda-Imene Ouzari
Journal:  Vaccines (Basel)       Date:  2022-06-06

5.  Vaccine-Mediated Activation of Human TLR4 Is Affected by Modulation of Culture Conditions during Whole-Cell Pertussis Vaccine Preparation.

Authors:  Marieke E Hoonakker; Lisa M Verhagen; Elder Pupo; Alex de Haan; Bernard Metz; Coenraad F M Hendriksen; Wanda G H Han; Arjen Sloots
Journal:  PLoS One       Date:  2016-08-22       Impact factor: 3.240

6.  Study on Toxicity Reduction and Potency Induction in Whole-cell Pertussis Vaccine by Developing a New Optimal Inactivation Condition Processed on Bordetella pertussis.

Authors:  Naser Mohammadpour Dounighi; Mehdi Razzaghi-Abyane; Mojtaba Nofeli; Hossein Zolfagharian; Fereshteh Shahcheraghi
Journal:  Jundishapur J Microbiol       Date:  2016-07-09       Impact factor: 0.747

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.